Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight

DelveInsight forecasts continued positive growth for the bispecific-antibody treatment market through 2036 across the U.S., EU4, UK and Japan, supported by expanding oncology and autoimmune pipelines; the 7MM recorded approximately 70,000 incident multiple-myeloma cases in 2025. Near-term catalysts include J&J's positive Phase III data for the Tecvayli-Talvey regimen and EU approval of AbbVie/Genmab's Tepkinly combination in relapsed/refractory follicular lymphoma. Risks remain material, highlighted by AstraZeneca's August 2026 discontinuation of its Phase III volrustomig lung-cancer trial after interim efficacy results.

Analysis

This is not a sector-wide revenue catalyst: the source provides no market-size estimate, pricing assumption, uptake curve, or probability-adjusted pipeline valuation. The investable implication is instead that bispecifics are transitioning from a novelty premium to a crowded modality, where value will accrue to assets that reduce cytokine-release/infection burden, enable community-oncology administration, or demonstrate superiority in earlier treatment lines. Developers without a clear safety, dosing, or biomarker-selection advantage face faster multiple compression as clinically similar programs proliferate.

JNJ is best positioned to monetize the modality’s maturation because an installed commercial and treatment-center footprint can lower incremental launch costs and reinforce regimen adoption in myeloma. The more consequential competitive pressure falls on single-asset lymphoma and myeloma developers: REGN’s linvoseltamab, ABBV/GMAB’s epcoritamab franchise, and Roche’s cevostamab must compete not only on response rates but on outpatient feasibility and sequencing after CAR-T. Over 6-18 months, administration complexity creates a less obvious beneficiary in oncology care infrastructure and drug-device workflows, while it constrains rapid penetration of products requiring intensive early-cycle monitoring.

AZN’s discontinued lung-cancer program is a useful warning against assigning platform-level value to a bispecific mechanism; target biology and trial design remain asset-specific. Conversely, CTMX’s conditional-activation collaboration with REGN could be strategically valuable if it widens the therapeutic window, but collaboration headlines alone do not establish economics, milestone timing, or clinical proof. The immediate trading signal is weak; the next 1-3 month catalysts are actual data releases, regulatory labels, and commercial commentary rather than this forecast publication.

Contrarian view: consensus may overestimate market expansion by treating each approval as additive. In hematologic malignancies, cross-trial comparability, infection prophylaxis costs, physician capacity, and payer step-edits can make the market a share-transfer exercise; in solid tumors, repeated late-stage setbacks imply that broad TAM forecasts deserve a steep probability discount. Falsify this caution if a bispecific demonstrates durable earlier-line superiority with materially lower hospitalization/monitoring requirements and receives a label supporting broad community use.

Key Decisions for Investors

• No directional trade on the publication itself; treat it as a screening item, not a catalyst. Require independently disclosed sales, formulary access, and treatment-duration data before underwriting a sector-growth rerating.
• Maintain a 6-12 month quality tilt toward JNJ versus a basket of clinical-stage bispecific developers (JANX, CMPX, IMCR, ZYME): JNJ can convert regimen adoption into revenue with limited binary-trial exposure, while the basket remains vulnerable to readout-driven drawdowns. Reassess if JNJ reports slowed TECVAYLI/TALVEY uptake or materially worsening discontinuation rates.
• Watch REGN versus ABBV/GMAB around lymphoma commercial updates and linvoseltamab regulatory milestones; do not initiate a pair until comparative outpatient dosing, infection rates, and duration of therapy are disclosed. A clear administration advantage for either product would be the relevant 1-3 month catalyst.
• Avoid using AZN’s discontinued volrustomig study as a standalone AZN short: the asset is immaterial to the diversified earnings base. It is, however, a negative read-through for unvalidated PD-1/CTLA-4 bispecific platform valuations; reduce exposure to comparable mechanism claims absent controlled efficacy data.
• Place an event alert on ZBIO for the overdue pivotal SLE data disclosure and on CTMX for clinical candidate selection or economics from its REGN alliance. These are binary, high-volatility situations; absent verified timing and endpoint details, they are watch items rather than recommendations.